Sun Pharma to increase stake in Ranbaxy Malaysia to 79.5 percent
New Delhi: Drug major Sun Pharmaceutical Industries on Thursday said it will increase stake in its subsidiary Ranbaxy Malaysia Sdn Bhd to 79.5 percent through the purchase of shares.
One of the wholly-owned subsidiaries of the company has agreed to increase its shareholding in Ranbaxy Malaysia Sdn Bhd by 8.3 percent by way of purchase of around 6.66 lakh shares, Sun Pharma said in a filing to the BSE.
Ranbaxy Malaysia Sdn Bhd, is a subsidiary of Sun Pharma, and the company along with one of its wholly owned arms has 71.2 percent shares prior to the acquisition, it added.
The share purchase will be for a cash consideration of MYR 2,861,365.65, Sun Pharma said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd